Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data.

@article{Bischof2009CosteffectivenessOD,
  title={Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data.},
  author={Matthias Bischof and Matthias Briel and Heiner C. Bucher and Alain J. Nordmann},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2009},
  volume={12 5},
  pages={649-56}
}
BACKGROUND There is only limited information about cost-effectiveness of drug-eluting compared with bare metal stents (BMS) over a time horizon of more than 1 year. METHODS AND RESULTS We developed a Markov model based on clinical outcome data from a meta-analysis including 17 randomized controlled trials comparing drug-eluting versus BMS with a minimum follow-up of 1 (n = 8221) and a maximum follow-up of 3 years (n = 4105) in patients with chronic coronary artery disease. Costs were obtained… CONTINUE READING